Upadacitinib + Placebo for Upadacitinib + Prednisolone
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Takayasu Arteritis (TAK)
Conditions
Takayasu Arteritis (TAK)
Trial Timeline
Feb 4, 2020 → Aug 1, 2028
NCT ID
NCT04161898About Upadacitinib + Placebo for Upadacitinib + Prednisolone
Upadacitinib + Placebo for Upadacitinib + Prednisolone is a phase 3 stage product being developed by AbbVie for Takayasu Arteritis (TAK). The current trial status is active. This product is registered under clinical trial identifier NCT04161898. Target conditions include Takayasu Arteritis (TAK).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04161898 | Phase 3 | Active |
Competing Products
1 competing product in Takayasu Arteritis (TAK)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tocilizumab | Chugai Pharmaceutical | Phase 3 | 77 |